Company Encyclopedia
View More
name
Hvsen Biotech
300871.SZ
Hvsen Biotechnology Co., Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. Its products include tylvalosin tartrate powders and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. The company produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives.
3.196 T
300871.SZMarket value -Rank by Market Cap -/-

Financial Score

08/11/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking63/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE12.20%B
    • Profit Margin12.92%B
    • Gross Margin33.28%C
  • Growth ScoreA
    • Revenue YoY48.74%A
    • Net Profit YoY570.79%A
    • Total Assets YoY1.56%C
    • Net Assets YoY48.80%A
  • Cash ScoreB
    • Cash Flow Margin774.02%B
    • OCF YoY48.74%A
  • Operating ScoreB
    • Turnover0.57B
  • Debt ScoreB
    • Gearing Ratio28.40%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Hvsen Biotech released its performance for the first three quarters, with a net profit attributable to the parent company of 188 million yuan, an increase of 494.28%

    Hvsen Biotech released its Q3 2025 report, with operating revenue for the first three quarters reaching 1.26 billion yuan, a year-on-year increase of 58.92%; net profit attributable to the parent company was 188 million yuan, a year-on-year increase of 494.28%; net profit excluding non-recurring gains and losses was 166 million yuan, a year-on-year increase of 611.92%; basic earnings per share were 1.0134 yuan

    Zhitong·
    SZ
    300871
    -0.97%
    Zhitong·
    SZ
    300871
    -0.97%

    Hvsen Biotech: Subsidiary "Yinqiao Lanjin Oral Solution" Obtains New Veterinary Drug Registration Certificate

    Wuhan Hvsen Biotech Co., Ltd.'s subsidiary Hubei Hvsen Biotech Co., Ltd. has obtained a new veterinary drug registration certificate from the Ministry of Agriculture and Rural Affairs for its "Yinqiao Lianqin Oral Solution." This drug is classified as a Class III new veterinary drug, primarily used for the prevention and treatment of respiratory diseases in chickens. Although the successful development of this product demonstrates the company's innovation capabilities, its short-term impact on performance is limited, and investors should be aware of the associated risks

    Zhitong·
    SZ
    300871
    -0.97%
    Zhitong·
    SZ
    300871
    -0.97%

    Hvsen Biotech: In the first half of this year, it has obtained 7 pet product approvals, greatly expanding its pet product line

    Hvsen Biotech stated on the investor interaction platform that the pet medicine sector is one of the key development directions of the company. The company is adjusting resource allocation and increasing investment in the research and development of pet medicines and the construction of market channels. It has established an independent and specialized pet medicine R&D team, and in the first half of this year, it has obtained 7 pet product approvals, greatly expanding its pet product line. The company's pet medicines mainly involve sub-sectors such as pet deworming, antipyretic and analgesic medications, dermatological drugs, internal medicine diseases, and functional health products

    Zhitong·
    SZ
    300871
    -0.97%
    Zhitong·
    SZ
    300871
    -0.97%

    Hvsen Biotech plans to invest CNY 170 million to implement a green equipment technological transformation project for veterinary raw materials

    Hvsen Biotech announced that the company will invest 170 million yuan to implement a green equipment technological transformation project for veterinary raw materials, upgrading the existing production line in two phases. The project aims to introduce efficient, energy-saving, and automated equipment to enhance production capacity, expand the fermentation product pipeline, and optimize the product structure

    Zhitong·
    SZ
    300871
    -0.97%
    Zhitong·
    SZ
    300871
    -0.97%

    Hvsen Biotech released its performance for the first half of the year, turning a loss into a profit of 117 million yuan

    According to the Zhitong Finance APP, Hvsen Biotech released its semi-annual report for 2025, showing an operating income of 822 million yuan, a year-on-year increase of 88.45%. The net profit attributable to shareholders of the listed company was 117 million yuan. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 99.301 million yuan. The basic earnings per share were 0.6622 yuan. In addition, it plans to distribute a cash dividend of 1.00 yuan (including tax) for every 10 shares to all shareholders

    Zhitong·
    SZ
    300871
    -0.97%
    Zhitong·
    SZ
    300871
    -0.97%